| pubmed-article:1662828 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1662828 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:1662828 | lifeskim:mentions | umls-concept:C0684249 | lld:lifeskim |
| pubmed-article:1662828 | lifeskim:mentions | umls-concept:C0005953 | lld:lifeskim |
| pubmed-article:1662828 | lifeskim:mentions | umls-concept:C0872916 | lld:lifeskim |
| pubmed-article:1662828 | lifeskim:mentions | umls-concept:C0449297 | lld:lifeskim |
| pubmed-article:1662828 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:1662828 | pubmed:dateCreated | 1992-2-18 | lld:pubmed |
| pubmed-article:1662828 | pubmed:abstractText | The aim of this study was to estimate bone-marrow blood flow (BMBF) in man and to correlate this with myelosuppression induced by cytostatic treatment dosed as a function of surface area. Twenty-four patients suffering from small-cell lung cancer participated in the study. Blood flow was measured with the xenon-133 washout technique. The 133Xe clearance measurement took place in conjunction with the pre-treatment bone-marrow staging procedure (ad modern Radner). Tissue samples were taken for microscopy and for the determination of the blood-to-tissue partition coefficient lambda. After the bone-marrow aspiration, 0.1-0.2 ml of 133Xe in saline was injected into the bone marrow and the cannula was removed. Following a hyperaemic phase of 12 min (7-16 min), monoexponential washouts were demonstrated. The median washout rate constant was 0.0063 min-1 (0.0038-0.0098 min-1). Lambda values of 0.3-3.5 ml g were found, but microscopy of the bone marrow showed a fairly large admixture of peripheral blood. Therefore, the lambda values should be taken with caution and absolute blood-flow values were not calculated. The results demonstrated no correlation between 133Xe clearance from crista iliaca and leucocyte or platelet suppression. | lld:pubmed |
| pubmed-article:1662828 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1662828 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1662828 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1662828 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1662828 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1662828 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1662828 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:1662828 | pubmed:issn | 0036-5513 | lld:pubmed |
| pubmed-article:1662828 | pubmed:author | pubmed-author:HansenMM | lld:pubmed |
| pubmed-article:1662828 | pubmed:author | pubmed-author:FribergLL | lld:pubmed |
| pubmed-article:1662828 | pubmed:author | pubmed-author:BülowJJ | lld:pubmed |
| pubmed-article:1662828 | pubmed:author | pubmed-author:JensenJJ | lld:pubmed |
| pubmed-article:1662828 | pubmed:author | pubmed-author:MadsenJJ | lld:pubmed |
| pubmed-article:1662828 | pubmed:author | pubmed-author:PetersenL JLJ | lld:pubmed |
| pubmed-article:1662828 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1662828 | pubmed:volume | 51 | lld:pubmed |
| pubmed-article:1662828 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1662828 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1662828 | pubmed:pagination | 559-63 | lld:pubmed |
| pubmed-article:1662828 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:1662828 | pubmed:meshHeading | pubmed-meshheading:1662828-... | lld:pubmed |
| pubmed-article:1662828 | pubmed:meshHeading | pubmed-meshheading:1662828-... | lld:pubmed |
| pubmed-article:1662828 | pubmed:meshHeading | pubmed-meshheading:1662828-... | lld:pubmed |
| pubmed-article:1662828 | pubmed:meshHeading | pubmed-meshheading:1662828-... | lld:pubmed |
| pubmed-article:1662828 | pubmed:meshHeading | pubmed-meshheading:1662828-... | lld:pubmed |
| pubmed-article:1662828 | pubmed:meshHeading | pubmed-meshheading:1662828-... | lld:pubmed |
| pubmed-article:1662828 | pubmed:meshHeading | pubmed-meshheading:1662828-... | lld:pubmed |
| pubmed-article:1662828 | pubmed:meshHeading | pubmed-meshheading:1662828-... | lld:pubmed |
| pubmed-article:1662828 | pubmed:meshHeading | pubmed-meshheading:1662828-... | lld:pubmed |
| pubmed-article:1662828 | pubmed:meshHeading | pubmed-meshheading:1662828-... | lld:pubmed |
| pubmed-article:1662828 | pubmed:meshHeading | pubmed-meshheading:1662828-... | lld:pubmed |
| pubmed-article:1662828 | pubmed:meshHeading | pubmed-meshheading:1662828-... | lld:pubmed |
| pubmed-article:1662828 | pubmed:meshHeading | pubmed-meshheading:1662828-... | lld:pubmed |
| pubmed-article:1662828 | pubmed:meshHeading | pubmed-meshheading:1662828-... | lld:pubmed |
| pubmed-article:1662828 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1662828 | pubmed:articleTitle | Clearance of xenon-133 from bone marrow in patients with small-cell lung cancer. | lld:pubmed |
| pubmed-article:1662828 | pubmed:affiliation | Department of Clinical Physiology and Nuclear Medicine, Bispebjerg Hospital, Denmark. | lld:pubmed |
| pubmed-article:1662828 | pubmed:publicationType | Journal Article | lld:pubmed |
